Floatz logo

Dp-B99

Cerebrovascular Disorder

D-Pharm Ltd.Phase 2Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Cerebrovascular Disorder cohort.

Asset / SponsorPhaseRating
WARFARIN
Seoul National University Hospital
Phase 4BBB
Acetylsalicylic Acid
Peking Union Medical College Hospital
Phase 3BB
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
Zhejiang Provincial People's Hospital
Phase 3BB
Lipitor
Sichuan Provincial People's Hospital
Phase 4BB
Tirofiban
Peking Union Medical College Hospital
Phase 3BB

View all 34 →

Same molecule, other indications

Dp-B99 is also rated in:

brain ischemiaDormant
CCC
Indicative ·
55 / 100
View asset →
ischemic strokeDormant
CCC
Indicative ·
50 / 100
View asset →
stroke disorderDormant
CCC
Indicative ·
49 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →